Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis
Gabriel N. Mannis(Stanford University), Thomas G. Martin(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Shigeki Ohtake(Kanazawa University), Anuj Mahindra(University of California, San Francisco), Masamitsu Yanada(Fujita Health University), Peter H. Sayre(Immune Tolerance Network), Weiyun Z. Ai(City College of San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Lloyd E. Damon(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Rebecca L. Olin(University of California, San Francisco), Yasushi Miyazaki(Nagasaki University), Aaron C. Logan(University of California, San Francisco), Claire Greene(University of California, San Francisco), T Naoe(Nagoya University), Catherine C. Smith(University of California, San Francisco), Jesús Caballero(Universitat Autònoma de Barcelona), Justin H. Hwang(University of Minnesota), Andrew D. Leavitt(University of California, San Francisco), Nobuhiko Emi(Fujita Health University), Jeffrey M. Venstrom(Foundation Medicine (United States)), K M Gaensler(University of California, San Francisco), Neel K. Gupta(University of California, San Francisco)
Cited by 13
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k